A Trial to Evaluate OPC 67683 in Participants With Pulmonary Sputum Culture-positive, Multidrug-resistant Tuberculosis (TB)

NCT00685360 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

481

Enrollment

INDUSTRY

Sponsor class

Conditions

Tuberculosis, Pulmonary
Tuberculosis, Multidrug Resistant
Extensively Drug-Resistant Tuberculosis

Interventions

DRUG: Delamanid
DRUG: Optimized Background Regimen (OBR)
DRUG: Placebo

Sponsor

Otsuka Pharmaceutical Development & Commercialization, Inc.